Dr. Sartor on Remaining Questions With Sipuleucel-T in mCRPC

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the remaining questions with sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer (mCRPC).

Sartor says more cellular studies need to be done with sipleucel-T in order to better understand the immune response and changes in the cells of patients treated with this agent.

Additionally, Sartor says, the activity of immunotherapy in ethnic groups should be explored further.